{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,11,12]],"date-time":"2023-11-12T23:10:27Z","timestamp":1699830627638},"reference-count":45,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2006,7,20]],"date-time":"2006-07-20T00:00:00Z","timestamp":1153353600000},"content-version":"vor","delay-in-days":10062,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Med. Pediatr. Oncol."],"published-print":{"date-parts":[[1979,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The biologic impact and clinical toxicity of Corynebacterium parvum administered at a dose of 5 mg\/M<jats:sup>2<\/jats:sup> by intravenous or subcutaneous routes were evaluated in 18 children receiving combination chemotherapy for maintenance of acute lymphoblastic leukemia (ALL) in remission. Several nonspecific immunologic and hematologic parameters were evaluated. Patients were also monitored for changes in cutaneous sensitivity to histamine. No changes in any parameter were observed in patients after only one course of C parvum injection. However, after 6\u201010 courses, glass\u2010adherent peripheral blood leukocytes of C parvum\u2010treated patients augmented the response of PHA\u2010stimulated autologous lymphocytes. In all nine patients studied who received C parvum injection subcutaneously for at least six months, there were significant increases in the mean bone marrow myelocyte\u2010erythrocyte (ME) volumes compared to pretreatment values. These results suggest that periodic evaluations are desirable in patients receiving repeated administration of C parvum, since changes in immunologic and hematologic responses may be demonstrable only after several injections. In contrast to the reported experience in adults, subcutaneous C parvum administration in children was not well tolerated, whereas intravenous infusion was generally well tolerated.<\/jats:p>","DOI":"10.1002\/mpo.2950060203","type":"journal-article","created":{"date-parts":[[2007,2,20]],"date-time":"2007-02-20T14:56:23Z","timestamp":1171983383000},"page":"101-114","source":"Crossref","is-referenced-by-count":1,"title":["An evaluation of corynebacterium parvum during remission maintenance therapy in pediatric patients with acute lymphoblastic leukemia"],"prefix":"10.1002","volume":"6","author":[{"given":"J.","family":"Lankford","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Nitschke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Wells","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Cox","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G. B.","family":"Humphrey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2006,7,20]]},"reference":[{"key":"e_1_2_1_2_2","doi-asserted-by":"publisher","DOI":"10.1002\/9780470720011.ch6"},{"key":"e_1_2_1_3_2","doi-asserted-by":"publisher","DOI":"10.1002\/9780470720011.ch11"},{"key":"e_1_2_1_4_2","doi-asserted-by":"publisher","DOI":"10.1084\/jem.145.1.45"},{"key":"e_1_2_1_5_2","first-page":"143","article-title":"Activation of the classical and alternate pathways of complement by Corynebacterium parvum","volume":"19","author":"McBride WH","year":"1975","journal-title":"Clin Exp Immunol"},{"key":"e_1_2_1_6_2","doi-asserted-by":"publisher","DOI":"10.1099\/00222615-6-4-527"},{"key":"e_1_2_1_7_2","first-page":"367","article-title":"Corynebacterium parvum as an immunotherapeutic anticancer agent","volume":"1","author":"Scott MT","year":"1974","journal-title":"Sem Oncol"},{"key":"e_1_2_1_8_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM197406202902506"},{"key":"e_1_2_1_9_2","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1093\/jnci\/57.3.555","article-title":"Comparison of the potentiation of specific tumor immunity in mice by Corynebacterium parvum or BCG","volume":"57","author":"Scott MT","year":"1976","journal-title":"J Natl Cancer Inst"},{"key":"e_1_2_1_10_2","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1093\/jnci\/56.5.985","article-title":"Experimental cancer immunotherapy: Comparison of tumor rejection in F344 rats given live Mycobacterium bovis (Strain BCG) and killed Corynebacterium parvum","volume":"56","author":"Likhite VV","year":"1976","journal-title":"J Natl Cancer Inst"},{"key":"e_1_2_1_11_2","first-page":"189","volume-title":"Corynebacterium parvum","author":"Isra\u00ebl L","year":"1975"},{"key":"e_1_2_1_12_2","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4613-4428-5_39"},{"key":"e_1_2_1_13_2","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4613-4428-5_41"},{"key":"e_1_2_1_14_2","first-page":"340A","article-title":"Phase I study of Doxorubicin, Oncovin, 6\u2010Mercaptopurine and prednisone (DOMP) in childhood acute lymphoblastic leukemia (ALL)","volume":"23","author":"Humphrey GB","year":"1975","journal-title":"Clin Res"},{"issue":"97","key":"e_1_2_1_15_2","first-page":"77","article-title":"Isolation of mononuclear cells and granulocytes from human blood","volume":"21","author":"B\u00f6yum A","year":"1968","journal-title":"Scand J Clin Lab Invest"},{"key":"e_1_2_1_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(64)90799-8"},{"key":"e_1_2_1_17_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(197202)29:2<402::AID-CNCR2820290222>3.0.CO;2-A"},{"key":"e_1_2_1_18_2","doi-asserted-by":"crossref","first-page":"63","DOI":"10.4049\/jimmunol.113.1.63","article-title":"Leukemic serum inhibition of PHA\u2010induced transformation","volume":"113","author":"Humphrey GB","year":"1974","journal-title":"J Immunol"},{"key":"e_1_2_1_19_2","doi-asserted-by":"publisher","DOI":"10.1084\/jem.136.2.207"},{"key":"e_1_2_1_20_2","first-page":"30","article-title":"Report of the committee on standardization. I. A method of evaluating skin test response","volume":"29","author":"Scherr MS","year":"1971","journal-title":"Ann Allergy"},{"key":"e_1_2_1_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/0091-6749(73)90059-6"},{"key":"e_1_2_1_22_2","first-page":"250","volume-title":"Nonparametric Statistics for the Behavioral Sciences","author":"Siegel S","year":"1956"},{"key":"e_1_2_1_23_2","unstructured":"HumphreyGB BarbosaJ CulbertS KompD: Unpublished observations."},{"key":"e_1_2_1_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/0008-8749(72)90073-1"},{"key":"e_1_2_1_25_2","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1093\/jnci\/55.1.29","article-title":"Brief communication: Daily intravenous infusions of Corynebacterium parvum in twenty patients with disseminated cancer: A preliminary report of clinical and biologic findings","volume":"55","author":"Isra\u00ebl L","year":"1975","journal-title":"J Natl Cancer Inst"},{"key":"e_1_2_1_26_2","first-page":"1335","article-title":"The accumulated effects of repeated systemic or local injections of low doses of Corynebacterium parvum in mice","volume":"36","author":"Scott MT","year":"1976","journal-title":"Cancer Res"},{"issue":"1","key":"e_1_2_1_27_2","first-page":"51","article-title":"The role of macrophages in the adjuvant effect of Corynebacterium parvum","volume":"78","author":"Sljivic V","year":"1976","journal-title":"Periodicum Biologorum"},{"key":"e_1_2_1_28_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(197607)38:1<119::AID-CNCR2820380121>3.0.CO;2-1"},{"key":"e_1_2_1_29_2","first-page":"181","article-title":"Phase I clinical trial of C. parvum","volume":"16","author":"Hirshaut Y","year":"1975","journal-title":"Proc Am Assoc Cancer Res"},{"key":"e_1_2_1_30_2","first-page":"409A","article-title":"Complement activation during immunotherapy with Corynebacterium parvum","volume":"23","author":"Biron H","year":"1975","journal-title":"Clin Res"},{"key":"e_1_2_1_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/B978-0-12-514550-3.50013-X"},{"key":"e_1_2_1_32_2","first-page":"1139","article-title":"Phase I study of Corynebacterium parvum in patients with solid tumors","volume":"59","author":"Band PR","year":"1975","journal-title":"Cancer Chemother Res"},{"key":"e_1_2_1_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0025-7125(16)31895-8"},{"key":"e_1_2_1_34_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(75)90462-6"},{"key":"e_1_2_1_35_2","first-page":"485","volume-title":"Immunological Aspects of Neoplasia","author":"Isra\u00ebl L","year":"1975"},{"key":"e_1_2_1_36_2","first-page":"396","article-title":"Chemotherapy of advanced breast cancer with a combination of cyclophosphamide, adriamycin, methotrexate and 5\u2010fluorouracil (CAMF) with and without C. parvum","volume":"17","author":"DeJager R","year":"1976","journal-title":"Proc Am Soc Clin Oncol"},{"key":"e_1_2_1_37_2","first-page":"265","article-title":"Chemoimmunotherapy of metastatic breast cancer with Corynebacterium parvum (CP): A double\u2010blind randomized trial","volume":"17","author":"Haskell CM","year":"1976","journal-title":"Proc Am Soc Clin Oncol"},{"key":"e_1_2_1_38_2","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1182\/blood.V49.1.29.29","article-title":"Bone marrow cellularity determination: Comparison of the biopsy, aspirate and buffy coat","volume":"49","author":"Gruppo RA","year":"1977","journal-title":"Blood"},{"key":"e_1_2_1_39_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(197604)37:4<1687::AID-CNCR2820370412>3.0.CO;2-A"},{"key":"e_1_2_1_40_2","first-page":"441","article-title":"The effect of Corynebacterium parvum on the humoral and cellular immune systems in patients with breast cancer","volume":"24","author":"Minton JP","year":"1976","journal-title":"Clin Exp Immunol"},{"key":"e_1_2_1_41_2","doi-asserted-by":"publisher","DOI":"10.1099\/00222615-6-3-261"},{"key":"e_1_2_1_42_2","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4613-4428-5_43"},{"key":"e_1_2_1_43_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(75)92109-1"},{"key":"e_1_2_1_44_2","first-page":"270","article-title":"Schedule dependence of cytosine arabinoside (ARA\u2010C) and methotrexate (MTX) for recurrent childhood lymphocytic leukemia (ALL)","volume":"17","author":"Rivera G","year":"1976","journal-title":"Proc Am Soc Clin Oncol"},{"key":"e_1_2_1_45_2","doi-asserted-by":"publisher","DOI":"10.1002\/mpo.2950030406"},{"key":"e_1_2_1_46_2","first-page":"1097","article-title":"Cyclophosphamide (NSC\u201026271) maintenance therapy after a second remission of childhood acute lymphoblastic leukemia: Comparative clinical trial (standard dose versus intermittent high dose versus Cyclophosphamide plus cytosine arabinoside [NSC\u201063878])","volume":"59","author":"Albo V","year":"1975","journal-title":"Cancer Chemother Rep"}],"container-title":["Medical and Pediatric Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fmpo.2950060203","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/mpo.2950060203","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,12]],"date-time":"2023-11-12T22:40:42Z","timestamp":1699828842000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/mpo.2950060203"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1979,1]]},"references-count":45,"journal-issue":{"issue":"2","published-print":{"date-parts":[[1979,1]]}},"alternative-id":["10.1002\/mpo.2950060203"],"URL":"https:\/\/doi.org\/10.1002\/mpo.2950060203","archive":["Portico"],"relation":{},"ISSN":["0098-1532","1096-911X"],"issn-type":[{"value":"0098-1532","type":"print"},{"value":"1096-911X","type":"electronic"}],"subject":[],"published":{"date-parts":[[1979,1]]}}}